Your browser doesn't support javascript.
loading
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset.
Tomasicchio, Michele; Jaumdally, Shameem; Wilson, Lindsay; Kotze, Andrea; Semple, Lynn; Meier, Stuart; Pooran, Anil; Esmail, Aliasgar; Pillay, Komala; Roberts, Riyaadh; Kriel, Raymond; Meldau, Richard; Oelofse, Suzette; Mandviwala, Carley; Burns, Jessica; Londt, Rolanda; Davids, Malika; van der Merwe, Charnay; Roomaney, Aqeedah; Kühn, Louié; Perumal, Tahlia; Scott, Alex J; Hale, Martin J; Baillie, Vicky; Mahtab, Sana; Williamson, Carolyn; Joseph, Rageema; Sigal, Alex; Joubert, Ivan; Piercy, Jenna; Thomson, David; Fredericks, David L; Miller, Malcolm G A; Nunes, Marta C; Madhi, Shabir A; Dheda, Keertan.
Afiliação
  • Tomasicchio M; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Jaumdally S; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Wilson L; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Kotze A; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Semple L; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Meier S; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Pooran A; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Esmail A; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Pillay K; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Roberts R; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Kriel R; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Meldau R; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Oelofse S; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Mandviwala C; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Burns J; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Londt R; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Davids M; Division of Anatomical Pathology, Department of Pathology, and.
  • van der Merwe C; Division of Anatomical Pathology, Department of Pathology, and.
  • Roomaney A; Division of Anatomical Pathology, Department of Pathology, and.
  • Kühn L; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Perumal T; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Scott AJ; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Hale MJ; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Baillie V; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Mahtab S; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Williamson C; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Joseph R; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Sigal A; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Joubert I; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Piercy J; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Thomson D; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Fredericks DL; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Miller MGA; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Nunes MC; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
  • Madhi SA; South African MRC Centre for the Study of Antimicrobial Resistance.
  • Dheda K; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.
Am J Respir Crit Care Med ; 209(7): 840-851, 2024 04 01.
Article em En | MEDLINE | ID: mdl-38226855
ABSTRACT
Rationale In the upper respiratory tract, replicating (culturable) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is recoverable for ∼4-8 days after symptom onset, but there is a paucity of data about the frequency and duration of replicating virus in the lower respiratory tract (i.e., the human lung).

Objectives:

We undertook lung tissue sampling (needle biopsy) shortly after death in 42 mechanically ventilated decedents during the Beta and Delta waves. An independent group of 18 ambulatory patients served as a control group.

Methods:

Lung biopsy cores from decedents underwent viral culture, histopathological analysis, electron microscopy, transcriptomic profiling, and immunohistochemistry.Measurements and Main

Results:

Thirty-eight percent (16 of 42) of mechanically ventilated decedents had culturable virus in the lung for a median of 15 days (persisting for up to 4 wk) after symptom onset. Lung viral culture positivity was not associated with comorbidities or steroid use. Delta but not Beta variant lung culture positivity was associated with accelerated death and secondary bacterial infection (P < 0.05). Nasopharyngeal culture was negative in 23.1% (6 of 26) of decedents despite lung culture positivity. This hitherto undescribed biophenotype of lung-specific persisting viral replication was associated with an enhanced transcriptomic pulmonary proinflammatory response but with concurrent viral culture positivity.

Conclusions:

Concurrent rather than sequential active viral replication continues to drive a heightened proinflammatory response in the human lung beyond the second week of illness and was associated with variant-specific increased mortality and morbidity. These findings have potential implications for the design of interventional strategies and clinical management of patients with severe coronavirus disease (COVID-19).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Am J Respir Crit Care Med Assunto da revista: TERAPIA INTENSIVA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: África do Sul

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Am J Respir Crit Care Med Assunto da revista: TERAPIA INTENSIVA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: África do Sul